Sai Parenterals Board Approves Un-audited Results, Director Re-appointments

Sai Parenterals Ltd announced the outcome of its Board Meeting held on August 11, 2026. The board approved the un-audited financial results (Standalone and Consolidated) for the quarter ended June 30, 2026, along with the Limited Review Report. Key personnel changes were approved, including the re-appointment of Mr. Anil Kumar Karusala as Director and Managing Director, and Mrs. Vijitha Gorrepati as Whole-time Director. Mr. Kunal Kakumanu was appointed as Additional and Executive Director. The company also approved variations in the utilization of IPO proceeds, including acquisitions in Saicriti Pharma Private Limited and Prathyak Laboratories Private Limited, and the incorporation of a new step-down subsidiary in the USA. Ratification of the ESOP Plan 2025 and its extension to subsidiaries were also approved.